Director/PDMR Shareholding
October 28, 2016 – Shire
plc (LSE: SHP, NASDAQ: SHPG) (the “Company”)
Notification of transactions by person
discharging managerial responsibilities
1. |
Details
of the person discharging managerial responsibilities (“PDMR”) /
person closely associated with them (“PCA”) |
a) |
Name |
Phil Vickers |
2. |
Reason for the
notification |
a) |
Position / status |
Head of Research and
Development - PDMR |
b) |
Initial notification /
amendment |
Initial
notification |
3. |
Details of the
issuer, emission allowance participant, auction platform,
auctioneer or auction monitor |
a) |
Name |
Shire plc |
b) |
LEI |
54930005LQRLI2UXRQ59 |
4. |
Details of the
transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transactions have been conducted |
a) |
Description of the
financial instrument, type of instrument |
Shire plc American Depositary Shares (“ADSs”) |
Identification
code |
ISIN:
US82481R1068 |
b) |
Nature of the transaction |
Vesting of deferred ADSs
pursuant to the terms of a deferred share award granted on November
11, 2013 (the “DSA”), and consequent receipt of ADSs. In accordance
with the terms of the DSA, upon vesting the number of ADSs to be
delivered was increased by an amount equivalent to the value of
dividends paid by the Company in respect of the deferred ADSs from
the date of grant to the date of vesting. Details of related
lapse of deferred ADSs are referenced in section 5. below. |
c) |
Price(s)
and volume(s) |
Price(s) |
Volume(s) |
N/A |
503 |
d) |
Aggregated
information |
N/A
(single transaction) |
e) |
Date of the transaction |
October 28, 2016 |
f) |
Place of the transaction |
N/A |
5. |
Details of the
transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transactions have been conducted |
a) |
Description of the
financial instrument, type of instrument |
Shire plc American Depositary Shares (“ADSs”) |
Identification
code |
ISIN:
US82481R1068 |
b) |
Nature of the transaction |
Lapse of deferred ADSs
pursuant to the terms of the DSA referenced in section 4. above. In
accordance with the terms of the DSA, the number of ADSs lapsed is
equivalent in value to Dr. Vickers’ tax liability arising from the
vesting of the deferred ADSs. |
c) |
Price(s)
and volume(s) |
Price(s) |
Volume(s) |
N/A |
438 |
d) |
Aggregated
information |
N/A
(single transaction) |
e) |
Date of the transaction |
October 28, 2016 |
f) |
Place of the transaction |
N/A |
Oliver Strawbridge
Senior Assistant Company Secretary
For further information please
contact:
Investor
Relations |
|
|
Sarah Elton-Farr |
seltonfarr@shire.com |
+44 1256
894157 |
Ian Karp |
ikarp@shire.com |
+1 781
482 9018 |
Robert Coates |
rcoates@shire.com |
+44 1256
894874 |
Media |
|
|
Gwen Fisher |
gfisher@shire.com |
+1 484
595 9836 |
Debbi Ford |
debbi.ford@shire.com |
+1 617 949 9083 |
NOTES TO EDITORS
About Shire
Shire is the leading global biotechnology company focused on
serving people with rare diseases and other highly specialized
conditions. We strive to develop best-in-class products, many of
which are available in more than 100 countries, across core
therapeutic areas including Hematology, Immunology, Neuroscience,
Ophthalmics, Lysosomal Storage Disorders, Gastrointestinal /
Internal Medicine / Endocrine and Hereditary Angioedema; and a
growing franchise in Oncology.
Our employees come to work every day with a shared mission: to
develop and deliver breakthrough therapies for the hundreds of
millions of people in the world affected by rare diseases and other
high-need conditions, and who lack effective therapies to live
their lives to the fullest.
www.shire.com